Clinical trials: Allogeneic Stem-Cell Transplant
Hematological Malignancies, Leukemia
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
This research study uses a drug called cyclophosphamide to decrease the incidence of GVHD in matched sibling hematopoietic stem cell transplant. In doing so, the goal of the study is to increase overall survival.
- Conditions
- Hematological Malignancies, Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT01315132
- Testing
- Matched Sibling Allogeneic Transplantation
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Treosulfan-based Conditioning for Transplantation in AML/MDS
The study hypotheses is that the introduction of dose escalated treosulfan, in substitution to busulfan, will reduce toxicity after allogeneic transplantation while improving myeloablation and and disease control in patients with…
- Trial name
- NCT00491634
- Testing
- treosulfan
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Dr. Avichai Shimoni MD
Hemorrhagic Cystitis
Evaluation of the Safety and Efficacy of LB-DTK-BKV in Patients With BK Virus-Associated Hemorrhagic Cystitis Following Allogeneic Hematopoietic Stem Cell Transplantation
The goal of this clinical trial is to assess efficacy of BK virus specific T cells (LB-DTK-BKV) to treat pediatric, adolescent, and adult patients with BK virus-associated hemorrhagic cystitis after allogenic hematopoietic stem…
- Trial name
- NCT07638332
- Testing
- LB-DTK-BKV, Standard-of-care
- Where
- 9 sites in South Korea
- Volunteers
- 42 people
- Sponsor
- LucasBio
Graft Versus Host Disease, Hematologic Malignancies
Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation
The purpose of this study is to determine if the incidence of Graft vs. Host Disease (GVHD) after non-myeloablative transplantation can be reduced by using a combination of three immune suppressive medication; sirolimus…
- Trial name
- NCT00146614
- Testing
- Sirolimus, Tacrolimus, Methotrexate
- Where
- 3 sites in United States
- Volunteers
- 105 people
- Sponsor
- Dana-Farber Cancer Institute
Leukemia, Lymphoma
Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant
RATIONALE: Zoledronic acid, vitamin D, and calcium may prevent bone loss in patients who are undergoing donor stem cell transplant.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Osteoporosis
- Trial name
- NCT00321932
- Testing
- calcium, cholecalciferol, zoledronic acid
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of Minnesota
Leukemia, Lymphoma
Unrelated Donor Transplant for Malignant and Non-Malignant Disorders
Unrelated matched donor (cord blood, bone marrow or peripheral blood) allogeneic stem cell transplantation (UDAlloSCT) with either myeloablative or reduced intensity conditioning will be well tolerated and result in a high degree…
- Conditions
- Leukemia, Lymphoma, Bone Marrow Failure Syndromes, Immunodeficiencies
- Trial name
- NCT01050439
- Testing
- UDAlloSCT, Therapy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Columbia University
Allogeneic Stem-Cell Transplant
Early Chimerism Following Allogeneic Stem-Cell Transplant
Allogeneic stem cell transplant (allo-SCT) is a common treatment for variety of blood cancers. To determine how many cells are from the donor after transplant, doctors complete a "chimerism analysis" or a test of participant…
- Trial name
- NCT03689907
- Testing
- Chimerism Evaluation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Hematopoietic and Lymphoid Cell Neoplasm, Hematopoietic Cell Transplantation Recipient
Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
This randomized pilot phase I trial studies the side effects of human lysozyme goat milk in treating patients with blood cancer undergoing a donor stem cell transplant.
- Trial name
- NCT03531281
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Etoposide
- Where
- United States
- Sponsor
- City of Hope Medical Center
CMV Infection, Persistent CMV Viremia
Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is to see how well transfusions of T-cells work in treating CMV. Tcells are a type of white blood cell that helps protect the body from infection.
- Trial name
- NCT02136797
- Testing
- CMVpp65 Specific T-cells
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Crohn Disease
Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease
This research study is investigating whether alpha beta T-cell depleted hematopoietic stem cell transplant (HSCT) can be an immune system replacement for Crohn disease patients and whether this is safe and effective for patients…
- Trial name
- NCT06986382
- Testing
- CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Prednisone/Methylprenisolone, Palifermin
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Stanford University
Fecal Microbiota Transplantation
Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer
Patients who have a gastrointestinal acute Graft versus host disease (GVHD) received a first-line standard treatment of corticosteroids. For patients who do not respond or progress after an initial response have a high mortality.
- Trial name
- HERACLES (NCT03359980)
- Testing
- fecal microbiota transfer
- Where
- 16 sites in France, Italy and 1 more
- Volunteers
- 24 people
- Sponsor
- MaaT Pharma
Sickle Cell Trait
Mobilization and Handling of Stem Cells for Transplant From Healthy Volunteers With Sickle Cell Trait
This study will examine the effects of granulocyte colony-stimulating factor (G-CSF) on bone marrow stem cells in healthy volunteers with sickle cell trait and determine if cells collected for transplantation from donors with…
- Trial name
- NCT00005782
- Testing
- Granulocyte colony-stimulating factor, Leukapheresis
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Peripheral Blood Stem Cell Transplantation, aGVHD
Valproic Acid With Methylprenisonlone for the Treatment of Acute GVHD
aGVHD remains as complication in patients after allogeneic stem cell transplantation. Methylprednisolone at 1~2mg/kg is considered as standard first-line treatment.
- Trial name
- NCT02848105
- Testing
- VPA
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Cytomegalovirus Infections, Hematological Disease
CMV-CTL for the Treatment of CMV Infection After HSCT
Human cytomegalovirus (CMV) infection is a major cause of morbidity and mortality for recipients of allogeneic hematopoietic stem cell transplantation(HSCT).
- Trial name
- NCT03004261
- Testing
- donor derived cytomegalovirus specific T lymphocytes, Foscarnet, Ganciclovir
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Steroid Refractory GVHD
Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease
Steroid-refractory graft-vs-host disease (SR-GVHD) is a major cause of mortality after allogeneic hematopoietic stem cell transplantation (HSCT).
- Trial name
- NCT05663827
- Testing
- Ruxolitinib
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- Yi-Lun Wang
Lymphoma, Myeloma
Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath
Allogeneic transplantation is used to treat many malignant and non-malignant diseases, though the potential toxicities of the procedure remain high.
- Conditions
- Lymphoma, Myeloma, Leukemia, Myelodysplasia
- Trial name
- NCT00578942
- Testing
- Campath Purged Non-myeloablative ASCT
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- David Rizzieri, MD
Hematologic Diseases, Stem Cell Transplant Complications
DSAs in Patients Undergoing Allo-HSCT From Mismatched Donors
Retrospective observational multicentric, spontaneous non-interventional non-pharmacological Italian study. The primary objective is analysis of Anti-HLA antibodies and DSAs searching and monitoring activities in haematological…
- Trial name
- AIBT_DSAs (NCT04888286)
- Where
- 25 sites in Italy
- Volunteers
- 912 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Related Donors Donating PBSC to a Family Member, Healthy Donors
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
This research study tests a new medicine for mobilizing stem cells so they can be collected and used for allogeneic stem cell transplant for treatment of hematological malignancies.
- Conditions
- Related Donors Donating PBSC to a Family Member, Healthy Donors, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT04762875
- Testing
- MGTA-145, Plerixafor
- Where
- 8 sites in United States
- Volunteers
- 7 people
- Sponsor
- Ensoma
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant
FLAT-Auto is a phase II trial. fludarabine and ARA-C will be combined with the alkylating agent treosulfan (FLAT), to investigate the feasibility and the efficacy of a new regimen, supported with autologous peripheral blood SCT…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Transplant-Related Hematologic Malignancy
- Trial name
- FLAT-Auto (NCT03961919)
- Testing
- Fludarabine, ARA-C, Treosulfan
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Ciceri Fabio
Cytomegaloviral Infection, Hematopoietic and Lymphoid System Neoplasm
A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
This phase Ib trial evaluates the safety and most effective dose of a cytomegalovirus (CMV) pp65 peptide-loaded alpha-type-1 polarized dendritic cell (CMV-alphaDC1) vaccination in patients who are undergoing an allogeneic…
- Trial name
- NCT05589844
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, CMV pp65 Peptide-loaded Alpha-type-1 Polarized Dendritic Cell Vaccine
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Roswell Park Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.